bee32 / iStockphoto.com
31 October 2017Americas
PTAB grants rehearing of Genentech patent IPR
The Patent Trial and Appeal Board (PTAB) has agreed to rehear an inter partes review (IPR) filed by Hospira, a company now owned by Pfizer.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Americas
7 March 2017 The Patent Trial and Appeal Board has rejected Celltrion’s challenge against a Genentech patent centring on a method of treating rheumatoid arthritis, stating that the challenged patent did not show any reasonable likelihood of being invalid.
Editor's picks
Editor's picks
Americas
7 March 2017 The Patent Trial and Appeal Board has rejected Celltrion’s challenge against a Genentech patent centring on a method of treating rheumatoid arthritis, stating that the challenged patent did not show any reasonable likelihood of being invalid.
Americas
7 March 2017 The Patent Trial and Appeal Board has rejected Celltrion’s challenge against a Genentech patent centring on a method of treating rheumatoid arthritis, stating that the challenged patent did not show any reasonable likelihood of being invalid.